A carregar...

Long Term Survival and Continued Complete Response of Vemurafenib in a Metastatic Melanoma Patient with BRAF V600K Mutation

Introduction. BRAF kinase inhibitors such as Vemurafenib have shown improvement in overall survival, progression-free survival, and response rates in patients with metastatic melanoma with BRAF V600K mutation. However, there were no cases of complete remission reported in patients with V600K mutatio...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Case Rep Oncol Med
Main Authors: Sahadudheen, K., Islam, Md. Rafiqul, Iddawela, M.
Formato: Artigo
Idioma:Inglês
Publicado em: Hindawi Publishing Corporation 2016
Assuntos:
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4775779/
https://ncbi.nlm.nih.gov/pubmed/26989536
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1155/2016/2672671
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!